Program
aflutinib
Also written as “Furmonertinib”, “Alflutinib” and “ASK120067”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Neoplasm Metastasis · Breast Neoplasms, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Allist Pharmaceuticals | 114 open or running | phase 3since Apr 12, 2021 | Nov 21, 2016 | Dec 2026phase 3 · NCT04853342 |
| Beijing Aosaikang Pharmaceutical | 41 open or running | phase 3since Oct 12, 2019 | Apr 10, 2018 | none ahead |
| ArriVent BioPharma | 33 open or running | phase 3since Oct 31, 2022 | Apr 6, 2022 | Feb 2029phase 3 · NCT07185997 |
| Abbisko Cayman | 11 open or running | phase 2since Oct 30, 2024 | Oct 30, 2024 | Dec 30, 2027phase 2 · NCT06668103 |
| Alphamab Oncology | 11 open or running | phase 1since Mar 5, 2025 | Mar 5, 2025 | Jun 30, 2028phase 1 · NCT06868732 |
| MediLink Therapeutics (Suzhou) | 11 open or running | phase 2since Sep 3, 2025 | Sep 3, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 7 studies since Nov 21, 2016.
- Apr 20, 2020Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT04360915 · 24 enrolled · China
- Apr 12, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04858958 · 90 enrolled · China
- Apr 12, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342 · 318 planned · China
- Jul 5, 2021Phase 1 study in NSCLCAllist Pharmaceuticals · NCT04958967 · China
- Apr 6, 2022ArriVent BioPharma's first study: phase 1 study in Carcinoma, Non-Small-Cell LungNew to ArriVent BioPharmaArriVent BioPharma · NCT05364073 · 160 enrolled · United States, Australia, Canada and more
- Jul 14, 2022Phase 2 study in NSCLCAllist Pharmaceuticals · NCT05466149 · 100 enrolled · China
- Oct 31, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT05607550 · 398 enrolled · United States, Australia, Brazil and more
- Nov 11, 2022Phase 1 study in Carcinoma, Non-Small-Cell LungBeijing Aosaikang Pharmaceutical · NCT05631678 · 48 enrolled · China
- Oct 30, 2024Abbisko Cayman's first study: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationNew to Abbisko CaymanAbbisko Cayman · NCT06668103 · 54 planned · China
- Mar 5, 2025Alphamab Oncology's first study: phase 1 study in Advanced Non-small Cell Lung CancerNew to Alphamab OncologyAlphamab Oncology · NCT06868732 · 288 planned · China
- Apr 9, 2025Phase 3 study in NSCLC Patients With Brain MetastasisAllist Pharmaceuticals · NCT06970639 · 380 planned · China
- May 20, 2025Phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419 · 338 planned · China
- Aug 15, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungArriVent BioPharma · NCT07185997 · 480 planned · United States, Australia, Canada and more
- Sep 3, 2025MediLink Therapeutics (Suzhou)'s first study: phase 2 study in Breast NeoplasmsNew to MediLink Therapeutics (Suzhou)MediLink Therapeutics (Suzhou) · NCT07169994 · 414 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungAllist Pharmaceuticals · NCT04853342
- Dec 30, 2027Primary completion: phase 2 study in Non-Small Cell Lung Cancer With EGFR MutationAbbisko Cayman · NCT06668103
- Jun 30, 2028Primary completion: phase 1 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT06868732
- Oct 31, 2028Primary completion: phase 3 study in NSCLCAllist Pharmaceuticals · NCT07010419
TargetBeta
“The mesylate salt form of alflutinib, an orally available selective inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, ”NCIt, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07169994Breast Neoplasms · China | 2 | Recruiting | MediLink Therapeutics (Suzhou) | Sep 1, 2026 | 414 |
| NCT07185997Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 3 | Recruiting | ArriVent BioPharma | Feb 2029 | 480 |
| NCT07010419NSCLC · China | 3 | Recruiting | Allist Pharmaceuticals | Oct 31, 2028 | 338 |
| NCT06970639NSCLC Patients With Brain Metastasis · China | 3 | Recruiting | Allist Pharmaceuticals | Mar 2029 | 380 |
| NCT06868732Advanced Non-small Cell Lung Cancer · China | 1 | Recruiting | Alphamab Oncology | Jun 30, 2028 | 288 |
| NCT06668103Non-Small Cell Lung Cancer With EGFR Mutation · China | 2 | Recruiting | Abbisko Cayman | Dec 30, 2027 | 54 |
| NCT05631678Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Aug 3, 2022 | 48 |
| NCT05607550Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | ArriVent BioPharma | Oct 6, 2026 | 398 |
| NCT05466149NSCLC · China | 2 | Active, not recruiting | Allist Pharmaceuticals | Jun 27, 2025 | 100 |
| NCT05364073Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 1 | Active, not recruiting | ArriVent BioPharma | Jun 3, 2025 | 160 |
| NCT04958967NSCLC · China | 1 | Withdrawn | Allist Pharmaceuticals | May 1, 2022 | 0 |
| NCT04858958NSCLC · China | 1 | Completed | Allist Pharmaceuticals | Dec 5, 2024 | 90 |
| NCT04853342Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Allist Pharmaceuticals | Dec 2026 | 318 |
| NCT04360915Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Beijing Aosaikang Pharmaceutical | Dec 30, 2019 | 24 |
| NCT04143607Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Mar 31, 2024 | 337 |
| NCT03941340Healthy Male Volunteers · China | 1 | Completed | Allist Pharmaceuticals | Sep 6, 2019 | 6 |
| NCT03926182Healthy Male Volunteers · China | 1 | Completed | Allist Pharmaceuticals | Apr 3, 2019 | 16 |
| NCT03502850Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Beijing Aosaikang Pharmaceutical | Jan 2021 | 507 |
| NCT03452592Advanced NSCLC Patients With T790M · China | 2 | Terminated | Allist Pharmaceuticals | Apr 21, 2021 | 220 |
| NCT03127449Advanced NSCLC · China | – | Terminated | Allist Pharmaceuticals | May 12, 2021 | 116 |
| NCT02973763NSCLC | 1 | Terminated | Allist Pharmaceuticals | Feb 4, 2021 | 14 |
How it is read
Names in the registry
- “Furmonertinib”, 6 entries
- “Alflutinib”, 3 entries
- “ASK120067”, 3 entries
- “Firmonertinib”, 2 entries
- “Furmonertinib 160mg”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Neoplasm Metastasis, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.